Screening for <scp>MASLD</scp> and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis
Our results suggest routine screening for MASLD in obesity clinics is not cost-effective with resmetirom as the available treatment. A prescreening with FIB-4 before TE did not increase economic efficiency.
Authors
- Charles Stoecker (ORCID: https://orcid.org/0000-0001-5438-9312)
- Yin Wang (ORCID: https://orcid.org/0000-0002-3554-656X)
- Arpan Mohanty (ORCID: https://orcid.org/0000-0002-8408-8075)
Institutions
- Tulane University (US)
- Boston Medical Center (US)
Publication Details
- Journal
- Obesity
- Published
- 2025-08-13
- DOI
- https://doi.org/10.1002/oby.70005
- Citations
- 1
- Primary Topic
- Nutritional Studies and Diet
- Type
- article
- Field-Weighted Citation Impact
- 1.88